1. The blood−brain barrier (BBB) represents the major impediment to successful delivery of therapeutic agents to target tissue within the central nervous system. Intracarotid alkylglycerols have been shown to increase the transfer of chemotherapeutics across the BBB. 2. We investigated the spatial distribution of intracarotid fluorescein sodium and intravenous lissamine-rhodamine B200 (RB 200)−albumin in the brain of normal and C6 glioma-bearing rats after intracarotid co-administration of 1-O-pentylglycerol (200 mM). To elucidate the mechanisms involved in the alkylglycerol-mediated BBB opening, intraluminal accumulation of fluorescein isothiocyanate (FITC)−dextran 40,000 was studied in freshly isolated rat brain capillaries using confocal microscopy during incubation with different alkylglycerols. Furthermore, 1-O-pentylglycerolinduced increase in delivery of methotrexate (MTX) to the brain was evaluated in nude mice. 
Introduction
The brain capillary endothelium plays a key role in the pathophysiology of various diseases of the CNS such as inflammatory disorders, tumors, ischemia, and seizures (Pardridge, 1998). The mechanisms of functional regulation and transport at the blood−brain barrier (BBB) are not well understood, and further investigation is needed to clarify both how BBB dysfunction is mediated in disease states and how transport systems at the barrier can be altered for therapeutic purposes. Currently, successful treatment of many brain disorders seems to be impossible even though highly active drugs exerting powerful effects at the target site have been developed. Their efficacy is limited by very low penetration across the BBB (Neuwelt et al., 1999) . Thus, enhancing or targeting drug delivery to the brain has become a major issue in experimental neurology. Chemical modification of drugs and the use of transport mediating agents or vector systems are possible strategies for drug targeting to the brain (Smith, 1993; Huwyler et al., 1996; Reszka et al., 1997; Kroll & Neuwelt, 1998 ; Jolliet-Riant & Tillement, 1999); however, the clinical benefit of such measures has still to be demonstrated. In contrast to this, methods to open the BBB such as hyperosmotic disruption of the BBB or bradykinin receptor-induced increase in barrier permeability have already been shown to be effective in the treatment of experimental brain tumors (Blasberg et al., 1990; Nomura et al., 1994; Elliott et al., 1996; Matsukado et al., 1996; Kroll et al., 1998) . Chemotherapy of malignant brain tumors in conjunction with osmotic opening of the BBB has been advanced to the stage of clinical trials and tumor response has been documented in both adults and pediatric patients (Gumerlock et al., 1992; Dahlborg et al., 1996; Doolittle et al., 2000) .
The inadequate drug delivery across the BBB is a major factor that explains the poor response rates of chemosensitive brain tumors (Siegal & Zylber-Katz, 2002) . Consequently, there is a need for new maneuvers designed to overcome the limited access of anticancer agents to the brain and to brain tumors. Recently, the transfer of a variety of chemotherapeutic drugs across the BBB was shown to be increased dramatically by intracarotid drug administration in the presence of short-chain alkylglycerols (Erdlenbruch et al., 2000; 2002) . The intracarotid injection of alkylglycerols resulted in a concentration-dependent accumulation of the coinjected drugs within the brain. The effect was rapidly reversible and variations in the chemical structure of the alkylglycerols allowed for modulation of the extent of increased barrier permeability (Erdlenbruch et al., 2003) . Of particular importance is the fact that there were no signs of toxicity in long-term experiments using intracarotid 1-O-pentylglycerol and 2-O-hexyldiglycerol in rats (Erdlenbruch et al., 2003) . In view of their low toxicity and the potent and well-controllable effects, intracarotid alkylglycerols are thought to be a very promising principle to facilitate the transport of therapeutics across the BBB. However, little is known about the distribution of the delivered drugs within the hemispheres and whether large compounds such as proteins will enter the brain after intracarotid alkylglycerols. Furthermore, there are only marginal insights into the mechanisms involved in alkylglycerolmediated BBB opening. Finally, nude mice represent the species mostly used for the treatment of experimental human brain tumor xenografts, but alkylglycerols were not administered in nude mice so far.
Therefore, the purpose of the present study was (a) to estimate the 1-O-pentylglycerolmediated increase in the penetration of small and large fluorescence markers into the brain of both normal and glioma-bearing rats and to investigate the spatial distribution of the different markers within the brain, (b) to elucidate the mechanisms of action of the alkylglycerols by studying the accumulation of fluorescein isothiocyanate (FITC)−dextran 40,000 (40 kDa) in freshly isolated rat brain capillaries using confocal microscopy and quantitative image analysis during incubation with different alkylglycerols, and (c) to demonstrate feasibility and effectivity of the permeabilizing effect of 1-O-pentylglycerol in nude mice by intracarotid coadministration with methotrexate (MTX).
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Methods
Drugs
The synthesis of 1-O-pentylglycerol and 2-O-hexyldiglycerol has been described in detail elsewhere (Erdlenbruch et al., 2000) . Purity of the products was assessed by HPLC and was above 99% in all experiments. Depending on the binding site of the alkyl group, up to 1% of the respective 1-O-or 2-O-positional alkyl isomers were found. No other by-products were identified. For the in vivo experiments, 1-O-pentylglycerol was used as the prototypical compound of the alkylglycerols and because long-term in vivo studies have demonstrated a lack of toxicity (Erdlenbruch et al., 2003) . Incubation with rat capillary preparations was performed in vitro using 1-O-pentylglycerol and 2-O-hexyldiglycerol, an effective derivative of the alkyldiglycerol family associated with no toxic effects at therapeutic levels (Erdlenbruch et al., 2003) .
Fluorescence markers of different molecular size were chosen to estimate the permeability of the BBB in the presence or absence of 1-O-pentylglycerol. In the animal experiments, low and high molecular fluorescence dyes were administered. Fluorescein sodium (MW 367 Da) was purchased from Merck (Darmstadt, Germany), and lissamine-rhodamine B200 (RB 200) and human albumin were obtained from Sigma-Aldrich (Deisenhofen, Germany). Fluorescein sodium was dissolved in physiological saline, forming a stock solution of 5%. For intracarotid use (80 mg kg -1 ), this solution was further diluted to a final concentration of 2.5% in accordance with the protocol for the respective treatment groups. RB 200 was coupled to albumin and purified as described by Klein et al. (1986) . FITC−dextran 40,000 (MW 40 kDa, Sigma-Aldrich) was used for in vitro investigation of alkylglycerol-dependent permeation of drugs across isolated rat brain microvessels.
MTX was purchased from Onco-Hexal AG (Holzkirchen, Germany) and a dose of 5 mg kg -1 body weight (BW) was given to nude mice. Control animals received intra-arterial MTX without 1-O-pentylglycerol. In these experiments, MTX was diluted with physiological saline to the desired final volume (100 l). For intracarotid coinjection with 1-O-pentylglycerol, a mixture of alkylglycerol and MTX was diluted with water. The concentration of 1-Opentylglycerol in the final solution was 200 mM and the osmolality of the injected solutions ranged from 421 to 448 mosm kg -1 . Within this range of osmolality, no permeability changes due to osmotic effects have to be expected.
Animal experiments
Male Wistar rats and male nude mice were kept under conventional controlled conditions (22°C, 55% humidity, and day−night rhythm) and had free access to a standard diet (V1534-000, Fa. sniff, Soest, Germany) and tap water. The nude mice were purchased from Charles River Laboratories (CD®-1 nude mice, Crl:CD1®-nu, Sulzfeld, Germany). The experiments were carried out in accordance with the German Law on the Protection of Animals.
The differential permeability of the BBB in the absence and presence of 200 mM 1-Opentylglycerol was investigated in tumor-free rats (n=19) and in rats bearing C6 gliomas (n=12) using small and large fluorescence markers. The delivery of MTX to the brain of tumor-free nude mice was evaluated in the absence and presence of 1-O-pentylglycerol (n=12). MTX was chosen for these experiments because (a) it is used in different treatment protocols of pediatric brain tumors, (b) it is known to exhibit poor penetration into the CNS after both intravenous and intra-arterial administration (Neuwelt et al., 1998; Erdlenbruch et al., 2000) , and (c) the effect of alkylglycerols on the transfer of MTX into the CNS has been thoroughly investigated in rats (Erdlenbruch et al., 2003) .
Tumor implantation
Wistar rats weighing 180−220 g received intraperitoneal ketamine/xylazine (90 g/7.5 g per g BW) and 1 10 5 C6 cells were inoculated into the right putamen as described previously (Erdlenbruch et al., 1998) . Briefly, rats were placed in a stereotaxic instrument (David Kopf Instruments, Tujunga, CA, U.S.A.) and 10 l of a suspension of C6 cells in RMPI 1640 medium was injected using a 10-l Hamilton syringe with a 26-gauge needle 1 mm anterior and 3 mm lateral to the bregma, and 5 mm deep to the dural surface. Tumors were allowed to grow until first signs of manifestation (first day of weight loss or second day of no weight gain, 14 2 days after tumor implantation). At this time, large tumors were found with only minor variability in tumor size (Figure 4 ). 
Intra-arterial drug administration
The intracarotid administration of the drugs to rats was performed as described previously (Erdlenbruch et al., 2003) . In brief, rats were anesthetized with intraperitoneal pentobarbital (50 mg kg -1 BW) followed by intravenous injections. Body temperature was maintained at 37.5°C, and arterial blood pressure and heart rate were monitored by a Statham transducer (Gould, Oxnard, CA, U.S.A.) throughout the experiments via the left femoral artery. The right external carotid artery was cannulated and the microcatheter system was filled with blood in a retrograde manner. Fluorescein sodium (80 mg kg -1 BW) or MTX (5 mg kg -1 BW) was injected into the right internal carotid artery either in the presence (simultaneously) or in the absence of 1-O-pentylglycerol (200 mM, mean dose 90 10 mg kg -1 BW). All solutions were heated to 37°C and sterile filtered immediately before administration. In rats, a total volume of 1.2 ml consisting of 800 l drug solution followed by rinsing with 400 l of isotonic saline was injected with a flow rate of 6 ml min -1 using a Hamilton dispenser (Microlab, Hamilton Bonaduz, Switzerland). During the injection, the common carotid artery was clamped. RB 200−albumin (200 l per 100 g BW) was administered intravenously 3 min before the intracarotid bolus of fluorescein sodium. RB 200−albumin was given to stain intravascular space as well as to assess the permeabilizing effect of 1-O-pentylglycerol on large compounds. A simultaneous intracarotid co-injection of both fluorescent dyes was not performed, since the viscosity and the volume of the infusate would be too high. At 5 min after the intracarotid administration of fluorescein, the brains were rapidly removed and frozen in isopentane (-50°C).
The nude mice were anesthetized by intraperitoneal ketamine/xylazine (75 mg per kg BW/5 mg per kg BW). The surgical procedure was the same as described for the rat experiments; however, the trachea and the femoral artery were not cannulated. A special fine and bent glass catheter was used to cannulate the external carotid artery. MTX (5 mg kg -1 BW) was administered simultaneously or without 1-O-pentylglycerol (200 mM, 105 29 mg kg -1 BW). A volume of 100 l of drug solution was injected followed by rinsing with 40 l of isotonic saline (total volume 140 l). At 5 min after the MTX administration, mice were perfused with Ringer's solution via the left ventricle, the brains were rapidly removed and stored at -20°C until further analysis.
Histological evaluation
For histology, the frozen brains were sectioned into 7 m slices. Either sagittal or coronal serial sections were made and air dried. Evaluation of the sections was performed using fluorescence microscopy (Zeiss Universal, Zeiss Göttingen, Germany). Na-fluorescein and RB 200 were visualized by use of filter combinations as described by Klein et al. (1986) . The histological preparations were assigned to the respective anatomical planes according to the stereotaxic atlas from König & Klippel (1963) . Serial coronal planes were used for quantitative interindividual comparison of the fluorescence intensity of the brain. The reference plane (zero) for coronal sections was a plane through the interaural line and distances were given from this plane to identify the respective section levels (König & Klippel, 1963) . Fluorescence intensity was measured semiquantitatively using a highresolution black and white camera (Kappa, CF8/1 DXC, Gleichen, Germany) and computerized image analysis.
Analysis of MTX concentrations
The concentrations of MTX in the brain tissue were determined separately in the right hemisphere (ipsilateral to the injection), in the left hemisphere (contralateral), and in the cerebellum (including brain stem) as described previously (Erdlenbruch et al., 2000) . In brief, organs were minced and homogenized in alkaline medium (NaOH 0.1 M, total volume 0.8 ml, pH=12−13). After neutralization with hydrochloric acid, MTX concentrations were determined by fluorescence polarization immunoassay (FPIA; Jolley et al., 1981) . The FPIA reagent systems were purchased from Abbott Laboratories, IL, U.S.A., and analyses were performed according to the operation manuals. Calibration curves for tissue concentrations of MTX were established for each assay. Values are given as pmol mg -1 wet weight.
In vitro experiments Capillary isolation
Rat brain capillaries were isolated as described by Miller et al. (2000) . In brief, capillaries (3−6 animals per preparation) were isolated using a modification of the procedure of Pardridge et al. (1985) . All steps were carried out at 4° C in pre-gassed (95% O 2 /5% CO 2 ) solutions. Keeping the tissue on ice and in well-gassed buffers was essential for preservation of transport function. Pieces of grey matter were gently homogenized in three volumes (v w -1 ) of buffer A (103 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl 2 , 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 15 mM HEPES) and, after addition of dextran (final concentration 30%), the homogenate was centrifuged at low speed. The resulting pellet was resuspended in buffer B (buffer A supplemented with 25 mM NaHCO 3 , 10 mM glucose, 1 mM Na-pyruvate, and 0.5% (w/v) bovine serum albumin (BSA)) and then filtered through a 200 m nylon mesh. The filtrate was passed over a glass bead column and, after washing with 500 ml buffer, the capillaries adhering to the beads were collected by gentle agitation. Capillaries were centrifuged, the pellet resuspended in ice-cold, gassed, BSA-free Krebs−Henseleit buffer and immediately used for transport experiments.
Confocal microscopy
Confocal microscopy was performed as described (Miller et al., 2000) . Briefly, capillaries were transferred to a covered Teflon incubation chamber containing 1.5 ml of pre-gassed Krebs−Henseleit medium with 1 M FITC−dextran 40,000 in the absence or presence of 1-O-pentylglycerol or 2-O-hexyldiglycerol at concentrations up to 20 mM. The chamber floor was a 4 4 cm glass coverslip to which the capillaries adhered and through which they could be viewed. All experiments were conducted at room temperature (18−20°C). The chamber was mounted on the stage of a Zeiss LSM 5 Pascal inverted confocal laser scanning microscope and viewed through a 63 or 40 water immersion objective. The 488-nm laser line, a 510-nm dichroic filter, and a 515-nm long-pass emission filter were employed. Low laser intensity was used to avoid photobleaching of the dyes. With the photomultiplier gain set, tissue autofluorescence was undetectable. Capillaries were first viewed under reduced transmitted light illumination. A field containing 2−5 capillaries was selected and a confocal fluorescence image was obtained. Capillaries contained mostly unbranched segments at least 100 m in length and were 5−8 m in diameter at pixel resolutions 0.2 m pixel -1 . Transmitted light and fluorescence micrographs showed the endothelium to be 1−1.5 m thick.
Fluorescence intensities were measured from stored images using NIH Image 1.61 or Scion Image software as described previously (Miller, 1995) . Owing to microscope adjustments and focusing the capillaries selected, the first image could be made 4 min after starting incubation. Since the appearance of FITC−dextran 40,000 within the capillary lumen was mediated by passive diffusion, equilibrium has to be expected at maximum effects. The background fluorescence intensity was subtracted and the average pixel intensity for each area was calculated. The value assigned to a capillary was the means of all selected areas. As there are uncertainties in relating cellular fluorescence to the actual concentration of an accumulated compound in cells and tissues with complex geometry (Sullivan et al., 1990; Miller & Pritchard, 1991) , data are reported here as average measured pixel intensity rather than estimated dye concentration.
Statistical evaluation
Mean values s.d. are presented unless otherwise indicated. For statistical analyses, one-way analysis of variance (ANOVA) was used.
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Results
In vivo experiments
To investigate the spatial distribution of small and large fluorescence markers in normal tumor-free rats, serial sections of the brains were analyzed at defined planes. In the absence of 1-O-pentylglycerol (control animals, n=5), fluorescein sodium and RB 200−albumin were detected only within the lumina of the cerebral vasculature and no differences in fluorescence intensity were registered between the ipsilateral and the contralateral hemisphere (Table 1 ) . Intracarotid injection of 1-O-pentylglycerol resulted in a marked transfer of both fluorescein and RB 200−albumin into the brain tissue ipsilateral to the injection (n=14, Figures 1 and 2 ). Almost no extravasation of the fluorescent dyes was found in the contralateral hemisphere. The ratio of ipsilateral to contralateral fluorescence intensity in the coronal sections was chosen to quantify the 1-O-pentylglycerol-induced increase in BBB permeability. The mean ratio for fluorescein amounted to 6.45 1.4 and for RB 200−albumin to 2.66 1.0 (Table 1) . The increase in the fluorescence intensity of fluorescein was considerably stronger than of the intravenously administered high molecular RB 200−albumin. Since the two fluorescent probes were not administered at the same site and circulation times were different, the fluorescence intensities could not be compared. Intraindividual regional differences in the extent of ipsilateral dye extravasation became apparent by analyzing serial sections from the entire brain (Figure 3 ). Contralateral tissue fluorescence was low in all brain areas ( Figure 3 ). As visualized in Figures 1 and 2 , extravasation of the fluorescence markers was slightly more prominent in the cortical regions. Only small interindividual variations were found when comparing the pattern of the 1-O-pentylglycerol-induced increase in fluorescence intensity of both of the fluorescent markers (Table 1 ). In an additional series of experiments, intracarotid MTX was given in the presence or absence of 200 mM 1-O-pentylglycerol to tumor-free nude mice. After intracarotid administration of MTX without alkylglycerols, low tissue concentrations were found in the brain parenchyma. MTX delivery to the brain was markedly increased by 1-O-pentylglycerol. The increase of MTX concentrations was found predominantly in the right hemisphere ipsilateral to the bolus injection (P<0.05). 
In vitro experiments
The permeation of FITC−dextran 40,000 across the walls of freshly isolated rat brain capillaries was measured using confocal laser scanning microscopy. Figure 6 shows representative experiments using control and 1-O-pentylglycerol-exposed capillaries. In the control capillary, little change in fluorescence was observed after 20 min. In contrast, 1-Opentylglycerol-exposed capillaries showed rapid increases in fluorescence. We used quantitative image analysis to measure dextran permeation into capillary lumens. Incubation of freshly isolated rat cerebral capillaries with 1 M FITC−dextran 40,000 in the absence and presence of 10 mM 1-O-pentylglycerol. Owing to microscope adjustments and focusing the capillaries selected, the first image could be made 4 min after starting incubation.
Whereas only negligible amounts of the paracellular marker compound in capillary lumens can be seen in control capillaries (left panel), a clear accumulation of FITC−dextran 40,000 was observed within 20 min in the lumina of capillaries incubated with 1-O-pentylglycerol (right panels). Arrows indicate the point on which the confocal microscope was focused. 
Discussion
The limited access of potentially helpful therapeutics into the CNS resulting from the presence of the BBB emphasizes the importance of developing strategies for overcoming the BBB. Only a limited number of approaches to increase the transfer of drugs to the brain have been used in clinical studies so far (Cornford & Hyman, 1999) . Osmotic opening of the BBB by intracarotid infusion of hypertonic mannitol solution has been reported to increase the delivery of water-soluble drugs, peptides, antibodies, and viral vectors to the brain (Rapoport, 2000) . This technique is used in conjunction with intra-arterial chemotherapy to treat human primary CNS lymphomas or high-grade malignant gliomas, and improved survival has been reported (Dahlborg et al., 1996; , 1996) and only a very modest increase in drug transfer to the tumor was achieved in animal models (Kroll et al., 1998) . In view of these difficulties, other strategies are in demand for the delivery of neuropharmaceuticals across the BBB.
Intracarotid short-chain alkylglycerols have been reported to induce a strong and transient increase in the transport of chemotherapeutic drugs to the ipsilateral hemisphere (Erdlenbruch et al., 2003) . One goal of the present study was to evaluate the extent and local distribution of alkylglycerol-mediated delivery of large compounds to the brain. Staining of brain parenchyma with albumin-bound RB 200 demonstrated that even proteins could enter the brain when administered in conjunction with 1-O-pentylglycerol. Thus, opening of the BBB using alkylglycerols permits brain delivery of drugs with a wide range of molecular size. From preliminary data using intracarotid globulin coupled fluorescence markers, it was inferred that even larger proteins could be transferred to the brain. In earlier experiments using chemotherapeutic drugs of different molecular size, it was shown that the amount of drug delivered to the CNS using 1-O-pentylglycerol decreased with increasing size of the coinjected compounds (Erdlenbruch et al., 2000) . The higher extravascular fluorescence intensities of small marker substances such as fluorescein sodium concur with the fact that 1-O-pentylglycerol-mediated enhancement of drug delivery to the brain depends on the molecular size of the injected drug. Furthermore, within the same brain section, tissue staining with fluorescein was more homogenous compared with RB 200−albumin, which exhibited a more spot-like, patchy extravasation predominantly around the vessels. This difference in the pattern of fluorescence can be explained by weaker and slower penetration of the large albumin-linked RB 200 into the brain parenchyma. From recent barrier experiments using different chemotherapeutics in rats, it was already assumed that both high molecular size and high polarity of the co-administered drugs are associated with lower CNS penetration, because 1-O-pentylglycerol-induced accumulation of vancomycin and gentamicin within the brain was significantly lower than that of cisplatin and MTX (Erdlenbruch et al., 2000) .
There was little interindividual variation in the regional distribution of the fluorescence markers in normal animals. This provides further evidence of the reliability of barrier opening by 1-O-pentylglycerol in the normal unchanged brain. Within the C6 gliomas, baseline permeability was heterogeneous. Increased vascular permeability of brain tumors has been well described in the literature (Hiesiger et al., 1986; Inoue et al., 1987; Neuwelt et al., 1998) and may account for some tumor responses to chemotherapy. In the present study, there was a strong increase in tissue fluorescence in both tumor tissue and surrounding ipsilateral normal brain reflecting similar permeabilizing effects of 1-O-pentylglycerol at the blood−brain tumor barrier and the intact barrier. Due to the high fluorescence intensity of the tumor tissue after administration of the fluorescent markers in the presence of 1-O-pentylglycerol, the exposure time had to be shortened substantially to avoid overexposure of the images. Therefore, no quantification of the increase in tissue fluorescence within the different brain regions could be performed. In earlier studies, however, the increase in drug delivery to brain tumor tissue and ipsilateral cortex after intracarotid administration of 1-O-pentylglycerol was analyzed using different chemotherapeutic drugs (Erdlenbruch et al., 2000; 2002) . The 1-O-pentylglycerolmediated increase in the transfer of methotrexate to tumor tissue was approximately as high as to the surrounding ipsilateral tumor-free brain (18-fold in the tumor as compared to 28-fold in the surrounding brain). Thus, the use of alkylglycerols in conjunction with intra-arterial chemotherapy enables enhanced access of anticancer drugs to the tumor mass and to infiltrative malignant cells at the tumor edge.
This contrasts with the effects observed after osmotic BBB disruption, because mannitol has been reported to increase drug delivery predominantly to the normal brain rather than to the tumor itself, resulting in a reversal of the tumor-to-cortex permeability relationship (Hiesiger et al., 1986; Inoue et al., 1987; Shapiro et al., 1988; Barnett et al., 1995; Neuwelt et al., 1998) . As the present study allowed no quantification of the 1-O-pentylglycerol-mediated increase in tumor uptake of the fluorescent markers, further studies using both mannitol and alkylglycerols are needed to compare the increase in drug transfer to different tumor areas and to the surrounding normal brain. Intra-arterial chemotherapy of brain tumor-bearing animals in conjunction with BBB opening by hyperosmolar mannitol or 1-O-pentylglycerol will clarify whether alkylglycerols offer any superiority over mannitol.
Since large molecular weight agents were also transported across the BBB, and in view of both the potential for exact regulation of barrier opening and the lack of long-term toxicity of short-chain alkylglycerol derivatives (Erdlenbruch et al., 2003) , other applications also appear to be of great promise. Therefore, it is noteworthy that increased drug transfer in the presence of alkylglycerols was easily reproducible in nude mice. The 1-O-pentylglycerol-mediated MTX accumulation found in tumor-free nude mice was less marked than in normal Wistar rats (Erdlenbruch et al., 2003) indicating that the permeabilizing effect of alkylglycerols may differ between different species. Improved transit of specific brain-targeted compounds to the brain tissue will be of great interest in the next few years because new and effective neuropharmaceutics have been designed recently.
The use of the optical sectioning capabilities of confocal microscopy allowed us to develop a procedure that can provide new insights into the mechanisms of alkylglycerol-associated increase in transendothelial drug transport. The selective intraluminal accumulation of the fluorescent markers indicated that permeation of the drugs was mediated by enhanced permeability of the zonulae occludens. Relevant transcellular transport could be excluded due to the lack of intracellular labeling of the endothelial cells. Even at high magnification there was no evidence for a transcytotic pathway of the marker. Incubation of low concentrations of alkylglycerols with synthetic membranes consisting of dipalmitoylglycerophosphocholine or dimyristoylglycerophosphocholine resulted in an impressive and concentration-dependent decrease in phase transition temperature (data not shown). From these data, alkylglycerolinduced fluidization of biological membranes was hypothesized, possibly acting via changes in tight-junctional integrity. This effect, however, appears to be short-lasting, because baseline permeability of the barrier was restored within a few minutes (Erdlenbruch et al.,  2000; 2003) . Furthermore, no clinical or neuropathological alterations were found 2 and 4 weeks after intracarotid 1-O-pentylglycerol treatment (Erdlenbruch et al., 2003) . Ongoing experiments focusing on functional alterations of tight junction proteins will contribute to further clarify the mechanisms involved in the alkylglycerol-mediated increase in BBB permeability.
In summary, a strong increase in delivery of fluorescence markers of different molecular weight to both normal brain and brain tumors was demonstrated in rats by intracarotid coadministration of 1-O-pentylglycerol. Increased drug transfer across the BBB was also observed after intracarotid 1-O-pentylglycerol in nude mice. The permeabilizing effect of the alkylglycerols is mediated at least in part by enhanced permeability of the tight junctions. 
Leukemia and Lymphoma (Hodgkin's and Non-Hodgkin's Disease)
Leukemias are cancers of the blood-forming organs, and lymphomas are cancers of the lymphatic tissues. In general, leukemias and lymphomas respond well to the conventional treatment methods of chemotherapy and radiation therapy. Because there are many different types of these cancers, treatment is based on the specific diagnosis of the disease.
LEUKEMIA
In the United States, more than 30,000 new cases of leukemia will be diagnosed in the coming year, and adult onset of the disease will account for 90% of these cases. Leukemia is not a single disease but a group of related diseases. There are no specific symptoms for leukemias; instead, symptoms are more generalized and include fatigue, weakness, unexplained weight loss, and pain. Most cases of leukemia are found during routine laboratory tests such as a complete blood count (CBC with differential).
Once the initial diagnosis of leukemia is made, further testing includes bone marrow aspiration, lumbar puncture, and excisional biopsies to determine the specific type of leukemia. When leukemias are detected, they are not classified by stages because they are systemic diseases and other organs such as the spleen, lymph nodes, liver, and central nervous system are already involved.
Leukemias are classified into acute and chronic forms. Cancerous cells rapidly reproduce and accumulate in both forms of the disease, crowding out normal white blood cells. The difference between the two forms of leukemia is that, in the acute form, bone marrow cells do not reach maturity and immature cells accumulate. In the chronic form, the cells appear mature but are abnormal and live longer than normal white cells. If left untreated, the majority of patients with an acute form of the disease have a life expectancy of 1 year.
Leukemias are further classified according to the type of affected bone marrow cells. The cancer is myelogenous if the involved blood cells are granulocytes or monocytes. The cancer is lymphocytic if the affected cells are lymphocytes. Leukemias are divided into four main types: acute myelogenous (AML), chronic myelogenous (CML), acute lymphocytic (ALL), and chronic lymphocytic (CLL). There are also several subtypes of these diseases based upon the French-American-British (FAB) classification system for acute leukemias. Prognosis and treatment are based on the diagnosis of the type and subtype of the disease.
Leukemias respond well to chemotherapy and radiation therapy, and these treatment methods are often used in combination. The treatment of leukemia involves the use of a combination of cancer medications given over a period of time. As a general rule, AML will be treated with high doses of chemotherapy agents over a short period of time, whereas ALL is treated with lower doses of chemotherapy over a longer period of time.
Chemotherapy agents attack rapidly dividing cells; however, they also interfere with the production of white blood cells, thereby exposing the patient to the risk of infection. Medications known as growth factors increase white blood cell counts and are often given in combination with chemotherapy. Interferons (IFN) are a group of naturally occurring biologic response modifiers that are sometimes used in the treatment of chronic leukemias (Aviles 1997). The most commonly used of these substances is interferon-alpha.
Interferon reduces the growth of cancerous cells, inhibits their replication, and enhances the immune system's response to the cancer. Interferon appears to be particularly useful when it is used as a maintenance therapy in patients with minimal residual disease (post-remission) or complete remission. In addition, all-trans retinoic acid (a vitamin A analogue), when used in combination with Interferon, may be useful in prolonging the lives of patients with promyelocytic leukemia and other forms of the disease (Zheng et al. 1996; Sacchi et al. 1997) . A cautionary note to the use of this therapy is that the patient may be at risk for thrombosis (blood clots). However, heparin therapy or the use of certain nutrients may reduce this risk (see the Thrombosis Prevention protocol).
Other therapies for the treatment of leukemias include stem-cell therapy. Stem-cell therapy involves removing stem cells from the patient either by bone marrow aspiration or by a procedure called apheresis (also called peripheral blood stem-cell (PBSC) transplant), when the cells are removed from the peripheral blood system. Stem cells may be obtained from the patient or from a donor who is a close tissue match to the patient. In this therapy, high doses of chemotherapy and radiation therapy destroy the patient's bone marrow, and the collected stem cells are then transplanted into the patient to restore normal blood cell production. This type of therapy is still in the experimental stage. As a result, it is very expensive and may not be covered by insurance.
HODGKIN'S LYMPHOMA
Hodgkin's lymphoma is a cancer of the lymph nodes. The American Cancer Society estimated that over 7400 new cases of the disease would be diagnosed in 2001. However, Hodgkin's disease has an overall cure rate of 75% in newly diagnosed cases. Slightly more than half of all newly diagnosed cases will occur in men.
Although it may affect any lymph tissue, Hodgkin's disease most commonly affects the supraclavicular, high cervical, or mediastinal nodes. Some patients exhibit no symptoms of the disease, although others may have fever, night sweats, or weight loss, among other symptoms. Most patients have one or more slow-growing, enlarged lymph nodes, but because swollen lymph nodes are more often associated with infections, patients often ignore this symptom. It is important to have any lymph node more than 1 cm (0.39 inches) in size evaluated by a physician, particularly if the node enlargement is not associated with infection.
If Hodgkin's disease is suspected, the patient may undergo magnetic resonance imaging (MRI) or computed tomography (CT) to determine the location(s) of enlarged nodes inside the body and to detect any abnormalities of the spleen or other organs that may be associated with the disease. Diagnosis is confirmed by any one of a number of biopsy techniques, including fine needle aspiration, excisional biopsy, or incisional biopsy. A bone marrow aspiration may also be used to stage the disease.
Once the diagnosis is made, it is important to stage the disease. Staging determines the disease's extent of involvement. This information is used to plan a treatment program and will affect the survival rate.
Clinical staging consists of a thorough patient history and physical examination, x-rays, and laboratory tests. Other diagnostic tools for staging include gallium scans and lymphangiograms (a type of x-ray). Some patients require pathological examination that involves a surgical procedure called a laparotomy (sometimes referred to as a staging laparotomy). The current staging system for Hodgkin's disease is the Ann Arbor Staging Classification system. Four stages (I, II, III, IV) of the disease are recognized, based upon the degree of involvement. Stage I disease is the least serious and Stage IV the most serious.
Hodgkin's lymphoma is treated using a combination of chemotherapy agents. There are two common chemotherapy combinations: mechlorethamine (Mustargen), vincristine (Oncovin), prednisone (Deltasone, Meticorten), and procarbazine (Matulane) or Adriamycin, bleomycin (Blenoxane), and dacarbazine (DTIC). The type of chemotherapy used will depend upon a number of factors, including the stage of the disease and the patient's age.
Radiation therapy is often used in combination with chemotherapy. Depending on the severity of the disease, radiation may involve the use of a focused beam of radiation or total nodal irradiation. As with all types of lymphomas, bone marrow transplantation or peripheral blood stem-cell transplantation may be considered in patients who do not respond to chemotherapy or radiation therapy.
NON-HODGKIN'S LYMPHOMA
The American Cancer Society estimated that nearly 56,200 new cases of non-Hodgkin's lymphoma (NHL) would be diagnosed in 2001. NHL is the fifth most common type of cancer in the United States. The disease is difficult to treat, with an average 1-year survival rate of 70% and a 5-year survival rate of 51%. Approximately 90% of all non-Hodgkin's lymphomas are diagnosed in adults.
The average age at diagnosis is in the early 40s, and the disease is slightly more common in men than in women. The risk for the disease increases throughout life. Other potential risk factors for the disease may include adult-onset diabetes of long duration and a history of previous cancers, according to a British study (Cerhan et al. 1997) . Survival rates for non-Hodgkin's lymphoma are variable, depending on the type of cell involved and the stage of the disease.
Non-Hodgkin's lymphomas are cancers that also affect the lymphatic system, particularly the lymphocytes--the cells responsible for maintaining the body's immune system. There are two major types of lymphocytes: B-cells and T-cells. B-cells are more common and are involved in approximately 85% of all non-Hodgkin's lymphomas.
Generalized symptoms of the disease include unexplained weight loss, fever, profuse sweating, and severe itchiness. The disease may affect the lymph nodes close to the body's surface (e.g., in the neck, groin, or underarm). These nodes become swollen and are usually noticeable to the patient. If lymph nodes in the abdomen are affected, the patient may experience abdominal swelling resulting from accumulating fluid or tumor growth. If lymph nodes near the intestines are affected, the patient may have difficulty with the passage of stools. When the lymphoma originates in the thymus, the growth of the tumor may block the trachea or the superior vena cava may become compressed, resulting in a lifethreatening condition known as superior vena cava (SVC) syndrome.
The disease is diagnosed by fine needle aspiration, incisional biopsy, or excisional biopsy. Other techniques used to assist in the diagnosis include x-rays, CT scans, and bone marrow aspiration. Because there are a number of different types of malignancies in non-Hodgkin's lymphomas, the types are classified according to two systems. The Working Formulation classifies these lymphomas based on prognosis: The categories are low, intermediate, and high-grade. The Revised European American Lymphoma (REAL) system divides NHL into types according to clinical behavior. The categories are indolent, aggressive, and highly aggressive. High-grade and highly aggressive tumors are the most difficult to treat.
Treatment for non-Hodgkin's lymphoma depends on the type of lymphoma (e.g., indolent or aggressive), the stage of the disease, the age of the patient, and the patient's overall health. As in Hodgkin's lymphomas, chemotherapy and radiation therapy are used to treat the disease. Bone marrow transplantation may be considered for patients who do not benefit from other forms of therapy. In one study, Interferon was found to be an effective treatment for low-grade lymphomas; however, intermediate-and high-grade tumors did not respond as well. Studies of B-cell non-Hodgkin's lymphomas also indicated that Interferon-gamma and -alpha might be useful in the treatment of certain types of the disease (Tourani et al. 1989; McLaughlin 1996) .
SIGNAL TRANSDUCTION PATHWAY INHIBITION--A NEW TREATMENT APPROACH
Information has emerged offering an entirely new approach to the treatment of leukemias and lymphomas. Early in the progression of these diseases, many, although not all, have been found to express certain cytokine chemical messengers or signal transduction pathways previously thought only to be expressed in human solid tumors as well as certain inflammatory and immunosuppressive cytokines. The blockade or inhibition of these signal transduction pathways in human solid tumors has yielded dramatic results. One example is the drug Iressa made by AstraZenca. Iressa has produced positive results in certain cancers via a blockade of the epidermal growth factor receptor site (EGFR) found to be over-expressed in many cancers (see the Cancer Adjuvant Therapy protocol for information on natural supplements that have been shown to inhibit certain signal transduction pathways).
Growth, pro-inflammatory, and immunosuppressive cytokines often expressed by leukemias and lymphomas are: The lymphomas and leukemias that can over-express these cytokines are: The recommended dose of vitamin A supplementation is 100,000-300,000 International Units (IU) daily. Monthly blood testing is necessary to monitor vitamin A liver toxicity.
Caution: Prior to considering vitamin A therapy, refer to the symptoms of vitamin A toxicity in Appendix A.
Vitamin D3 and its analogs may induce certain leukemia and lymphoma cancer cells to differentiate into normal cells. If vitamin D3 supplements are used, the typical dose for cancer patients is 4000 IU a day.
Monthly blood tests to monitor serum calcium, kidney function, and liver function are necessary to prevent vitamin D3 toxicity. Although not specifically recommended for patients with chronic lymphocytic leukemia, vitamins A and D3 may be beneficial because of their effects against a wide range of cancer cells.
Soy Extract A potentially beneficial adjuvant approach for leukemia and lymphoma uses soy extracts with high genistein content. Genistein is an inhibitor of protein tyrosine kinase, the enzyme that cancer cells require in order to replicate. A study conducted to assess the effects of genistein in several types of cancer showed that protein kinase C activity was inhibited, subsequently retarding the growth of cancer cells (Carlo-Stella et al. 1996a; 1996b) .
Studies suggest that genistein may also enhance the effects of chemotherapy via a blockade of a number of signal transduction pathways. These are: The blockade or inhibition of these important signal transduction pathways is dose-dependent, that is, more is better.
In patients whose tumor cells have mutant p53 oncogenes, the benefits of soy extracts may be even more significant, since genistein, from soy, has been shown to down-regulate mutant p53 oncogenes. One key to a tumor's response to treatment is the presence or absence of a functional p53 tumor suppressor gene, which produces a protein that cells need to undergo apoptosis (i.e., to die) when damaged. If p53 is functional, cancer cells damaged by radiation or chemotherapy self-destruct. However, if the genetic changes that lead to cancer also inactivate the p53 gene, which appears to occur in about half of all human malignancies, the cancer defies treatment. If the test for mutant p53 is positive, then soy extract therapy may be very beneficial. The Foundation realizes that many cancer patients desiring to use soy extracts may not be able to have immunochemistry testing for mutant p53. Patients may wish to consult their physicians to determine if mutant p53 was discovered during diagnosis of their disease.
The most concentrated form of soy extract available is Ultra Soy Extract. The recommended dose for cancer patients is five 700-mg capsules taken 4 times daily.
Curcumin An extract of the spice turmeric, curcumin is synergistic with the soy isoflavone, genistein, and has a number of cytokine-inhibiting properties, such as the inhibition of angiogenic signals from tissue-like bone marrow, as well as the down-regulation of pro-inflammatory cytokines.
Curcumin has also been shown to: Based on the multiple favorable mechanisms listed above, higher dose curcumin would appear to be useful for cancer patients to take.
Concerning curcumin being taken at the same time as chemotherapy drugs, there are contradictions in the scientific literature. Some studies indicate significant benefit, whereas other studies hint at reduced benefit or even potential toxicity. One study involving curcumin's concomitant use with the chemotherapy drug, Irinotecan, indicated potential toxicity (Michaels et al. 2001 ). Therefore, Life Extension recommends that curcumin not be taken in combination with this drug. Irinotecan is also known by the names Camptosar and CPT-11.
Chemotherapy drugs are highly toxic. Whether high-dose curcumin is beneficial or detrimental, depends on the type and dose of the chemotherapeutic drug used, the kind of cancer cell being attacked, and the dose of curcumin. Until more definitive information is published, we prefer to err on the side of caution and recommend that chemotherapy patients wait 3 weeks after their last dose of chemotherapy before taking high doses of curcumin. A high-dose of curcumin is 3600 mg taken 3 times a day. This high dose is sometimes consumed for 6-12 months and then reduced.
Green Tea
The primary action of green tea is through its catechin, EGCG, which blocks the induction of vascular endothelial growth factor (VEGF), considered essential in angiogenesis. GLA/DHA The down-regulation of inflammatory cytokines is fundamental to the control and eradication of the disease process. As previously noted, many leukemias and lymphomas over-express the inflammatory cytokines TNF-alpha and IL-6. Essential fatty acids are derived from sources such as fish, primrose, and borage oils. The docosahexaenoic acid (DHA) and gamma-linolenic acid (GLA) portions of these fatty acids have been shown to suppress these dangerous cytokines (Purasiri et al. 1997; De Caterina et al. 2000) . Additionally, the use of GLA and DHA has been shown to improve leukemia's response to chemotherapy (Liu et al. 2000) .
Statin Drugs A family of oncogenesknown as rasoften governs the regulation of cancer cell growth. The RAS family is responsible for modulating the regulatory signals that govern the cancer cell cycle and proliferation. A class of drugs known as the statins (used to control cholesterol) has also been found to induce apoptosis (cell death) in cancers that express the rasmutation. Acute myeloid leukemia strongly expresses the H-Rras mutation and has been found to be highly sensitive to one of the newer statins called cerivastatin. Cerivastatin has been found to be at least 10 times more potent at inducing apoptosis in AML than any previous statin drug ( Wong et al. 2001 ).
DHEA An interesting study (Inserra et al. 1998) showed that the hormone DHEA (dehydroepiandrosterone) favorably modulated the immune dysfunction that occurred during murine leukemia retrovirus infection in old mice. Leukemia is associated with deregulated cytokine production. When leukemic mice were given DHEA supplements, the loss of the cytokines, interleukin-2 and interferon-gamma was prevented (Araghi-Niknam et al. 1997). DHEA also suppressed the excessive production of the dangerous cytokines, interleukin-6 and interleukin-10. This preliminary study indicates DHEA might be effective in treating the immune dysfunction in those leukemia patients with a DHEA deficiency (especially older people).
Caution: DHEA is contraindicated in both men and women with certain hormone-related cancers (please refer to the DHEA Replacement Therapy protocol for complete information on the proper use of DHEA supplements).
Alpha-Lipoic Acid Alpha-lipoic acid (also known as lipoic acid) is a powerful antioxidant that has demonstrated effects against brain damage, aging, and diabetes. It may also help kill cancerous cells and retard heart disease.
A remarkable study shows how lipoic acid can reverse aging. Researchers at the University of California at Berkeley took liver cells from aging rats and measured how energized they were, how many free radicals were present, and how well the cells could recycle vitamin C. The aged rats were 3 times less active than the young ones. Free radicals were 5 times higher, the generation of energy had plummeted, and the ability to recycle ascorbic acid (vitamin C) was about half. After 2 weeks on lipoic acid, everything was reversed. Ascorbic acid levels rose, free radicals decreased, and energy levels took off. Levels of glutathione, an important antioxidant for the liver, were also protected by lipoic acid (Lykkesfeldt et al. A big question is whether a person undergoing chemotherapy should take antioxidants such as lipoic acid. Since generating free radicals is one of the ways chemotherapeutic drugs work, there is concern that taking antioxidants could keep chemotherapy from working. The jury is still out. Some studies show that antioxidants ameliorate the toxic effects of chemotherapy without affecting the ability of the drug to work. Others show that antioxidants reduce the effectiveness of the drugs--at least in cell culture. It may depend on the type of cancer, the drug used, and the dose of antioxidant. People undergoing chemotherapy have reported positive effects, but this is something that should be discussed with an oncologist (refer to the protocols entitled Cancer Chemotherapy and Cancer: Should Patients Take Dietary Supplements? for additional information about using antioxidants with chemotherapy).
Shark Liver Oil Alkylglycerols were first isolated from shark liver oil by Dr. Astrid Brohult, a physician in Sweden. Dr. Brohult was treating children with leukemia, with little success. Because white blood cells are produced in the bone marrow, she started to feed bone marrow from calves to the sick children. The result of this bone marrow feeding was a marked improvement in the immune systems and white blood cell counts of the children. Unfortunately, Dr. Brohult was unable to get the children to eat enough bone marrow to sustain these results, so she set out to find the active ingredient in bone marrow and isolate it. With the help of her husband, it was determined that alkylglycerols were responsible for the immune system-enhancing effects. Next, they discovered that alkylglycerols are found in the livers of cold-water sharks, such as the Greenland Shark. The shark in general has attracted attention because cancer occurrence is very rare in sharks. The existence of alkylglycerols in the liver of sharks may be one reason for the natural immunity to cancers.
The biologic effects of shark liver oil include stimulation of blood leukocyte and thrombocyte production (Le Blanc et al. 1995), as well as the activation of macrophage and antitumor activity.
Other effects include the ability to protect against radiation damage during radiation therapy for various types of cancer. Alkylglycerols act as a powerful immune system booster against infectious disease and help give nursing animals, including breast-fed babies, protection against infection until their own immune systems can fully develop. Shark liver oil has been around for 40 years and has been used as both a preventive and therapeutic agent. Not only have alkylglycerols been used to treat leukemia, as in the case of the children in Sweden, but they have also been used to prevent radiation sickness stemming from radiation cancer treatments. Furthermore, the high level of alkylglycerols that exist naturally within any given tumor cell has led scientists to postulate that this may be an apparent attempt of the body to control cell growth. Protein kinase C, an essential step in cancer cell growth, can actually be stopped or inhibited by alkylglycerols. In addition, it has been suggested that alkylglycerols directly act on the macrophages (large immune cells that "gobble up" cancer cells). Overall, alkylglycerols are able to stimulate the macrophage to secrete more than 50 substances concerned directly or indirectly with the immune system. Some of these substances, the interleukins, are powerful immune system fighters that interact with lymphocytes (Pugliese et al. 1998; 1999) .
Resveratrol
Resveratrol, a phytoextract found in grapes and red wine may act as a chemotherapeutic agent and inhibit the growth of various leukemia and melanoma cell lines.
Resveratrol is a plant polyphenol found in grapes and red wine. A study published in the journal Blood indicates that resveratrol effectively inhibits acute myelogenous leukemia (AML) cells in vitro through From the in vitro studies cited above, an appropriate human dosage cannot be extrapolated.
Monthly Blood Markers
Because all cancer therapies produce individual responses based on factors such as the type of disease, patient's age, and the presence of other diseases, the Foundation recommends monthly blood markers and other diagnostic testing to monitor the benefits of any supplemental therapies. The results of these tests provide critical information to evaluate the effectiveness of nonconventional therapies. If tumor indicators do not decrease after the initiation of any nonconventional therapy, patients should discontinue their use and seek other alternatives immediately.
Inhibiting Protein-Tyrosine Kinase with Gleevec In the various cancer protocols discussed in this book, references are made to nutrients like curcumin, genistein, and tocopherol succinate that function as protein-tyrosine kinase inhibitors. Because tyrosine kinases induce hyperproliferation of cancer cells, inhibiting these kinases has been shown to slow cancer cell propagation.
A drug called Gleevec (formerly known as STI571) is a protein-tyrosine kinase inhibitor that specifically interferes with the Bcr-Abl tyrosine kinase--the typical chromosomal abnormality seen in chronic myeloid leukemia (CML). Gleevec inhibits proliferation and induces apoptosis in Bcr-Abl cell lines as well as fresh leukemic cells from "Philadelphia chromosome positive" chronic myeloid leukemia (CML). Gleevec may also inhibit growth of other types of cancer cells.
Gleevec (imatinib mesylate) was first made available to patients with chronic myeloid leukemia (CML) in May 2001 after the results of exciting clinical studies were released in Europe. Gleevec is indicated for the treatment of patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.
The effectiveness of Gleevec is continuously being evaluated for efficacy, though it is now an FDAapproved drug. To read about the latest findings on Gleevec, log on to a special website www.gleevec.com.
It is interesting to note that a drug that functions along a similar mechanism as certain dietary supplements was put on the FDA's "fast-track" for approval.
CONCLUSION
Leukemia, Hodgkin's lymphoma, and non-Hodgkin's lymphoma generally respond well to conventional therapies. There are many different types of these diseases; therefore, chemotherapy and radiation therapy are individualized. Patients who do not respond well to chemotherapy and radiation therapy may benefit from other treatments such as bone marrow transplantation or a peripheral blood stem-cell transplant. In addition to conventional treatment, there are a number of alternative therapies available. Patients with certain types of leukemia or lymphoma may derive beneficial effects from Vesanoid, vitamin A, vitamin D3, curcumin, green tea, and soy extracts. It is imperative that patients have regular monitoring of tumor markers (or tumor size) to assess the usefulness of any treatment. Consult your hematologist or oncologist prior to initiating alternative treatments.
SUMMARY
